The European Medicines Agency (EMA) announced, on Friday 9 April, that an investigation had been opened by its safety committee (PRAC) to assess the risks of thromboembolic events linked to the Covid-19 vaccine produced by the pharmaceutical company Janssen Pharmaceutica NV, a Belgian subsidiary of the US group Johnson & Johnson.
The PRAC “has started a review of a safety signal”: in other words, the reports it has received about these thromboembolic events (blood clots, leading to the...